Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type
NCT05477264
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
38
Enrollment
OTHER
Sponsor class
Conditions
Lymphoma
Interventions
DRUG:
Tislelizumab
Sponsor
Won Seog Kim